Table 5:
TE Versus Biopsy for the Diagnosis of Liver Fibrosis—Additional Analyses
| Author, Year | Diagnosis | Positive LR (95% CI) | Negative LR (95% CI) | DOR (95% CI) | |
|---|---|---|---|---|---|
| Liver Disease | Fibrosis Stage | ||||
| Bota et al, 2013 (35) | Multiple diseasesa | F ≥ 2 | 4.79 (2.92–7.88) | 0.26 (0.19–0.35) | 18.3 (8.8–38.1) |
| F = 4 | NR | NR | NR | ||
| Friedrich-Rust et al, 2008 (37) | Multiple diseasesa | F ≥ 2 | NR | NR | NR |
| Kwok et al, 2014 (39) | NAFLD | F ≥ 2 | 3.05 (2.58–3.61)b | 0.30 (0.23–0.40)b | 10.80 (7.61–15.34)b |
| F ≥ 3 | 5.00 (3.58–6.99)b | 0.26 (0.18–0.36)b | 20.29 (10.61–38.79)b | ||
| F = 4 | 9.58 (6.01–15.28)b | 0.12 (0.06–0.25)b | 94.22 (39.56–238.90)b | ||
| Shaheen et al, 2007 (40) | Multiple diseasesa | F ≥ 2 | NR | NR | 7.2 (3.2–16.2) |
| Steadman et al, 2013 (42, 43) | HBV | F ≥ 2 | 2.94 (1.28–6.79)b | 0.34 (0.27–0.44)b | 8.74 (5.22–14.63)b |
| F ≥ 3 | 4.12 (3.16–5.37)b | 0.23 (0.15–0.36)b | 19.23 (11.96–30.90)b | ||
| F = 4 | 5.16 (3.90–6.83)b | 0.42 (0.33–0.55)b | 13.52 (8.4–21.76)b | ||
| HCV | F ≥ 2 | 4.40 (2.00–9.67)b | 0.25 (0.16–0.41)b | 17.59 (8.59–36.02)b | |
| F ≥ 3 | 8.52 (4.91–14.79)b | 0.14 (0.11–0.19)b | 75.14 (33.0–171.09)b | ||
| F = 4 | 7.48 (4.43–12.62)b | 0.22 (0.16–0.30)b | 37.59 (22.20–63.64)b | ||
| NAFLD | F ≥ 2 | 3.03 (2.50–3.68)b | 0.32 (0.23–0.44)b | 9.88 (6.20–15.72)b | |
| F ≥ 3 | 5.11 (3.51–7.43)b | 0.25 (0.16–0.39)b | 20.28 (9.66–42.58)b | ||
| F = 4 | 14.76 (6.65–32.78)b | 0.13 (0.06–0.29)b | 113.85 (39.83–325.43)b | ||
| Talwalkar et al, 2007 (45) | Multiple diseasesa | F ≥ 2 | 4.2 (2.4–7.2) | 0.31 (0.22–0.43) | 15 (9.8–24.6) |
| F = 4 | 11.7 (7.9–17.1) | 0.14 (0.10–0.20) | 87 (60.0–127.9) | ||
| Tsochatzis et al, 2011 (46) | HCV | F ≥ 2 | NR | NR | 13.9 (8.5–22.8) |
| F = 4 | NR | NR | 46.5 (26.7–91.0) | ||
| HBV | F ≥ 2 | NR | NR | 17.9 (7.7–41.7) | |
| F = 4 | NR | NR | 34.3 (17.0–69.2) | ||
| Tsochatzis et al, 2015 (47, 48) | HCV | F ≥ 2 | 4.16 (3.04–5.69)b | 0.29 (0.24–0.35)b | 16.29 (10.05–26.40) |
| F ≥ 3 | 7.13 (5.49–9.26)b | 0.17 (0.11–0.24)b | 52.84 (29.83–93.61)b | ||
| F = 4 | 9.21 (7.67–11.06)b | 0.16 (0.12–0.21)b | 64.36 (47.56–87.09)b | ||
| HBV | F ≥ 2 | 3.65 (2.43–5.50)b | 0.38 (0.29–0.49)b | 12.43 (6.26–24.70)b | |
| F ≥ 3 | 4.21 (3.30–5.37)b | 0.38 (0.28–0.50)b | 13.64 (9.08–20.49)b | ||
| F = 4 | 5.03 (3.86–6.92)b | 0.19 (0.12–0.29)b | 32.89 (17.90–60.44) | ||
| NAFLD | F ≥ 2 | 3.66 (1.45–9.22)b | 0.17 (0.09–0.32)b | 24.64 (5.49–110.62)b | |
| F ≥ 3 | 3.16 (2.70–3.69)b | 0.29 (0.23–0.38)b | 11.19 (8.03–15.58)b | ||
| F = 4 | 8.02 (6.16–10.42)b | 0.08 (0.02–0.26)b | 114.83 (40.23–327.81)b | ||
| ALD | F ≥ 2 | NR | NR | NR | |
| F ≥ 3 | 4.71 (3.38–6.56)b | 0.17 (0.09–0.33)b | 31.68 (80.06)b | ||
| F = 4 | 4.93 (3.56–6.83)b | 0.20 (0.15–0.26)b | 25.34 (14.42–44.53)b | ||
Abbreviations: ALD, alcoholic liver disease; CI, confidence interval; DOR, diagnostic odds ratio; HBV, hepatitis B virus; HCV, hepatitis C virus; LR, likelihood ratio; NAFLD, nonalcoholic fatty liver disease; NR, not reported; TE, transient elastography.
a
Aggregate results compiling multiple causes of liver diseases as reported in original studies; summary of included diseases provided in Table 2.
b
Calculated based on the number of true positives/false positives/false negatives/true negatives information provided in the published review using random effects models; see Appendix 3 for a sample graph.